Search

Displaying results 5971 - 5980 of 10000 in total
  1. Drug

    Lexatumumab

    go.drugbank.com/drugs/DB06599
    Investigational

    Lexatumumab is a fully humanized, high-affinity immunoglobulin G(1 lambda) monoclonal antibody (mAb).

  2. Drug

    Candoxatril

    go.drugbank.com/drugs/DB00616
    Experimental

    Candoxatril is the orally-active prodrug of candoxatrilat (UK-73967), a potent neutral endopeptidase (NEP) inhibitor.

  3. Drug

    SR 140333

    go.drugbank.com/drugs/DB05790
    Experimental

    SR 140333 is tachykinin antagonist which has potential to treat diarrhoea due to food allergy or inflammatory bowel disease.

  4. Drug

    Aminocandin

    go.drugbank.com/drugs/DB05128
    Experimental

    Aminocandin is a new representative of the echinocandins that could potentially affect the cellular morphology and metabolic status of Candida albicans cells within biofilms.

  5. Drug

    Desoxyribonuclease

    go.drugbank.com/drugs/DB09551
    ApprovedInvestigational

    Desoxyribonuclease is a crystalline enzyme that aids in the digestion of the thymus nucleic acid. … The enzyme's cofactor is reported to be magnesium (or manganese) ions, although the optimal concentration of the ion is independent of the enzyme concentration [A31251].

    Synonyms: Deoxyribonuclease I bovine
  6. Drug

    AMG 108

    go.drugbank.com/drugs/DB05545
    Investigational

    AMG 108 was investigated for use as an antirheumatic agent.

  7. Drug

    Lorcainide

    go.drugbank.com/drugs/DB13653
    Experimental

    Categories: Antiarrhythmics, Class I, Antiarrhythmics, Class Ic
  8. Drug

    Benazeprilat

    go.drugbank.com/drugs/DB14125
    Experimental

    Categories: Agents Acting on the Renin-Angiotensin System
  9. Drug

    Bithionol

    go.drugbank.com/drugs/DB04813
    ApprovedWithdrawn

    Bithionol, formerly marketed as an active ingredient in various topical drug products, was shown to be a potent photosensitizer with the potential to cause serious skin disorders. … Approvals of the NDA's for bithionol drug products were withdrawn on October 24, 1967 (see the Federal Register of October 31, 1967 (32 FR 15046)).

  10. Drug

    Flavin adenine dinucleotide

    go.drugbank.com/drugs/DB03147
    Approved

    (Lehninger, Principles of Biochemistry, 1982, p972) Flavin adenine dinucleotide is approved for use in Japan under the trade name Adeflavin as an ophthalmic treatment for vitamin B2 deficiency.